Brivaracetam for status epilepticus: a systematic review - PubMed
7 hours ago
- #Systematic Review
- #Status Epilepticus
- #Brivaracetam
- Brivaracetam (BRV) is a novel antiseizure medication being evaluated for status epilepticus (SE), refractory status epilepticus (RSE), and super-refractory status epilepticus (SRSE).
- A systematic review of 12 studies involving 263 patients showed a 56% seizure cessation rate after BRV administration, mostly within 72 hours.
- BRV was administered in varying doses: intravenous loading doses ranged from 50 to 400 mg, followed by maintenance doses of 80-400 mg per day.
- Common adverse events included drowsiness and psychiatric effects, reported in nine studies.
- The review highlights BRV's potential efficacy across different seizure types and etiologies but notes limitations in the current literature.